About Us

Welcome to RESTEM. We are a leading clinical-stage biopharmaceutical company focused on the discovery and development of patient-specific, as well as off-the-shelf and ready-to-use, next-generation cell therapies that are designed to activate and enhance a patient’s own immune system. Our therapies are designed to enable the treatment of a broad range of disabling diseases that improve patient outcomes, as well as overall health and wellness for patients around the world.

RESTEM’s cell therapy platform technology consists of two programs, our umbilical cord lining stem cells (ULSCs), and our natural killer cell (NK) therapeutics. Moreover, we are also developing next-generation cell therapy derivatives based on these two platforms.

Our mission

Our mission is to develop transformative, next-generation cell therapies that have the potential to revolutionize medicine and routine clinical care. We are dedicated to bringing these therapies to patients as rapidly as possible.

learn more

our cells

Our scientists have dedicated decades to groundbreaking research in the study of human cell biology and the development of novel cell therapies that can activate and enhance an individual’s immune system and overall health.

learn more

Our team

RESTEM’s innovative group of accomplished scientists, advisors, and professionals are dedicated to providing the safest and most effective cellular therapies that optimize health, longevity, and wellness to patients around the world.

learn more

Our clinical Trials

We are dedicated to improving health and wellness by enhancing the unique power of the human immune system based on our clinical therapeutic platforms. We have multiple ongoing clinical trials, with several new trials on the horizon. Our current clinical trial program is based on two platform technologies. Our proprietary Umbilical Cord Lining Stem Cell (ULSC) therapy is designed to target serious conditions that include cardiovascular disease, autoimmune disease, and other degenerative diseases. Our NK cell therapy program is designed to target senescence and age-associated disorders.